The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Oral Sildenafil in Infants With Persistent Pulmonary Hypertension of the Newborn: A Pilot Randomized Blinded Study
Abstract
BACKGROUND. Persistent pulmonary hypertension (PPHN) occurs in as many as 6.8 of 1000 live births. Mortality is ∼10% to 20% with high-frequency ventilation, surfactant, inhaled nitric oxide, and extracorporeal membrane oxygenation but is much higher when these therapies are not available. Sildenafil is a phosphodiesterase inhibitor type 5 that selectively reduces pulmonary vascular resistance. OBJECTIVE. Our goal was to evaluate the feasibility of using oral sildenafil and its effect on oxygenation in PPHN. DESIGN. This study was a proof-of-concept, randomized, masked study in infants >35.5 weeks' gestation and <3 days old with severe PPHN and oxygenation index (OI) >25 admitted to the NICU (Hospital Niño Jesús, Barranquilla, Colombia). The sildenafil solution was prepared from a 50-mg tablet. The first dose (1 mg/kg) or placebo was given by orogastric tube <30 minutes after randomization and every 6 hours. Preductal saturation and blood pressure were monitored continuously. OI was calculated every 6 hours. The main outcome variable was the effect of oral sildenafil on oxygenation. Sildenafil or placebo was discontinued when OI was <20 or if there was no significant change in OI after 36 hours. RESULTS. Six infants with an OI of >25 received placebo, and 7 received oral sildenafil at a median age of 25 hours. All infants were severely ill, on fraction of inspired oxygen 1.0, and with similar ventilatory parameters. Intragastric sildenafil and placebo were well tolerated. In the treatment group, OI improved in all infants within 6 to 30 hours, all showed a steady improvement in pulse oxygen saturation over time, and none had noticeable effect on blood pressure; 6 of 7 survived. In the placebo group, 1 of 6 infants survived. CONCLUSIONS. Oral sildenafil was administered easily and tolerated as well as placebo and improved OI in infants with severe PPHN, which suggests that oral sildenafil may be effective in the treatment of PPHN and underscores the need for a large, controlled trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oral Sildenafil in the Treatment of Erectile Dysfunction
Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D., & Wicker, P. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805143382001 · Cited by 2,120
Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial
Ghofrani, H. A., Wiedemann, R., Rose, F., Schermuly, R. T., Olschewski, H., Weissmann, N., Gunther, A., Walmrath, D., Seeger, W., & Grimminger, F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11024-5 · Cited by 769
Michelakis, E., Tymchak, W., Lien, D., Webster, L., Hashimoto, K., & Archer, S. (2002) · Circulation · doi:10.1161/01.cir.0000016641.12984.dc · Cited by 577
Oral sildenafil in the treatment of erectile dysfunction
Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D., Wicker, P. A., & Sildenafil Study Group (2002) · Journal of Urology · doi:10.1016/s0022-5347(02)80386-x · Cited by 502
Clinical efficacy of sildenafil in primary pulmonary hypertension
Sastry, B. K. S., Narasimhan, C., Reddy, N. K., & Raju, B. S. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.10.056 · Cited by 488
Turko, I. V., Ballard, S. A., Francis, S. H., & Corbin, J. D. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26391-4 · Cited by 193
Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: A review
Travadi, J., & Patole, S. (2003) · Pediatric Pulmonology · doi:10.1002/ppul.10389 · Cited by 96
Neurologic, Psychological, and Aggressive Disturbances with Sildenafil
Milman, H. A., & Arnold, S. B. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a402 · Cited by 92
Shekerdemian, L. S., Ravn, H. B., & Penny, D. J. (2004) · Pediatric Research · doi:10.1203/01.pdr.0000112033.81970.c2 · Cited by 77
Sildenafil as a treatment for pulmonary hypertension
Carroll, W. D. (2003) · Archives of Disease in Childhood · doi:10.1136/adc.88.9.827 · Cited by 76
Cited by
Abman, S. H., Hansmann, G., Archer, S. L., Ivy, D. D., Adatia, I., Chung, W. K., Hanna, B. D., Rosenzweig, E. B., Raj, J. U., Cornfield, D., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000329 · Cited by 1,164
Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions
Francis, S. H., Blount, M. A., & Corbin, J. D. (2011) · Physiological Reviews · doi:10.1152/physrev.00030.2010 · Cited by 639
Pediatric Pulmonary Hypertension
Ivy, D. D., Abman, S. H., Barst, R. J., Berger, R. M. F., Bonnet, D., Fleming, T. R., Haworth, S. G., Raj, J. U., Rosenzweig, E. B., Schulze Neick, I., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.028 · Cited by 536
Physiology of Transition from Intrauterine to Extrauterine Life
Hillman, N. H., Kallapur, S. G., & Jobe, A. H. (2012) · Clinics in Perinatology · doi:10.1016/j.clp.2012.09.009 · Cited by 456
Haworth, S. G., & Hislop, A. A. (2009) · Heart · doi:10.1136/hrt.2008.150086 · Cited by 305
Metadata
- Authors
- Baquero, H., Soliz, A., Neira, F., Venegas, M. E., & Sola, A.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2006-04-01
- Volume
- 117
- Issue
- 4
- Pages
- 1077-1083
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2125534535
- Cited by
- 334
- References
- 16
- FWCI
- 15.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral Sildenafil in Infants With Persistent Pulmonary Hypertension of the Newborn: A Pilot Randomized Blinded Study. https://app.cochat.ai/papers/10.1542/peds.2005-0523
- The paper
- Baquero, H., Soliz, A., Neira, F., Venegas, M. E., & Sola, A. (2006). Oral Sildenafil in Infants With Persistent Pulmonary Hypertension of the Newborn: A Pilot Randomized Blinded Study. Pediatrics. https://doi.org/10.1542/peds.2005-0523
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.